Page last updated: 2024-11-06

alpha-tocopherol phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Alpha-tocopherol phosphate (TP) is a synthetic compound derived from vitamin E (alpha-tocopherol). It is created by phosphorylating the hydroxyl group of alpha-tocopherol. TP is a potent antioxidant that exhibits unique properties compared to its precursor, alpha-tocopherol. It has been studied for its potential therapeutic applications in various medical conditions, including neurodegenerative diseases, inflammatory disorders, and cancer. TP is believed to exert its beneficial effects through multiple mechanisms, including its ability to scavenge free radicals, modulate intracellular signaling pathways, and protect cells from oxidative stress. Research on TP is ongoing to explore its potential as a therapeutic agent in a range of diseases and to understand its pharmacokinetic and pharmacodynamic properties.'

alpha-tocopherol phosphate: RN given refers to (2R*(4R*,8R*))-(+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID94493
CHEMBL ID4211176
SCHEMBL ID2507605
MeSH IDM0059654

Synonyms (51)

Synonym
alpha-tocopherol phosphate
AKOS000369851
38976-17-9
[(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate
tocopheryl phosphate
p7q15mlx1x ,
(2r-(4r*,8r*))-(1)-3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2h-benzopyran-6-yl dihydrogen phosphate
unii-p7q15mlx1x
einecs 254-231-9
unii-v7ez83setp
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-((4r,8r)-4,8,12-trimethyltridecyl)-, 6-(dihydrogen phosphate), (2r)-
d-alpha-tocopherol phosphate
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, dihydrogen phosphate, (2r-(2r*(4r*,8r*)))-
71276-50-1
v7ez83setp ,
alpha-tocopherol phosphate, d-
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-((4r,8r)-4,8,12-trimethyltridecyl)-, dihydrogen phosphate, (2r)-
alpha-tocopheryl phosphate, d-
alpha-tocopherol, phosphate
CS-3215
HY-16686
j313.906i ,
d-.alpha.-tocopherol phosphate
.alpha.-tocopherol, phosphate
.alpha.-tocopherol phosphate, d-
.alpha.-tocopheryl phosphate, d-
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, dihydrogen phosphate
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, dihydrogen phosphate, (2r*(4r*,8r*))-(+/-)-
j213.188i ,
dl-.alpha.-tocopheryl phosphate
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, 6-(dihydrogen phosphate)
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-((4r,8r)-4,8,12-trimethyltridecyl)-, 6-(dihydrogen phosphate), (2r)-rel-
.alpha.-tocopherol phosphate, dl-
6-chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, dihydrogen phosphate
.alpha.-tocopheryl phosphate, dl-
DTXSID50221445
SCHEMBL2507605
afae'a centa' nota inverted exclamation markafasa'a|afae'adaggeratrade mark?-tocopherol (phosphate)
alpha-tocopherol (phosphate)
rel-(r)-2,5,7,8-tetramethyl-2-((4r,8r)-4,8,12-trimethyltridecyl)chroman-6-yl dihydrogen phosphate
JUIUXBHZFNHITF-IEOSBIPESA-N
vitamin e phosphate
a-tocopherol phosphate
[2r-(4r*,8r*)]-(+/-)-3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2h-benzopyran-6-yl dihydrogen phosphate
DTXSID50902489
dl-alpha-tocopheryl phosphate
CHEMBL4211176 ,
bdbm50458519
tocp;vitamin e phosphate
F77833
dl-alpha-tocopherol phosphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In contrast to arachidonic acid, oleic acid was not toxic to the Hep G2-MV2E1-9 cells."( Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1.
Cederbaum, AI; Chen, Q; Galleano, M, 1997
)
0.3
" When administered daily for 28 days by gavage at doses up to 955 mg/kg bw/day (780 mg tocopherol equivalents/kg bw/day), MTP produced no consistent, dose-dependent adverse effects in rats."( Evaluation of the safety of mixed tocopheryl phosphates (MTP) -- a formulation of alpha-tocopheryl phosphate plus alpha-di-tocopheryl phosphate.
Bolton, L; Geytenbeek, S; Gianello, R; Libinaki, R; Ogru, E, 2006
)
0.33
" The 1% diet (equivalent to 587 and 643 mg mixed tocopheryl phosphates/kg body weight/day for male and female rats, respectively) was considered the no observed adverse effect level."( Subchronic oral toxicity study of mixed tocopheryl phosphates in rats.
Gianello, R; Hall, WC; Kennepohl, E; Libinaki, R; Ogru, E,
)
0.13
" The safety profile was consistent with the application method and known side-effect profile of oxycodone and naltrexone."( Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study.
Gavin, PD; Schlagheck, T; Shakib, S; Simon, LS; Smith, AJ, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
"To characterize the pharmacokinetic profile and evaluate the safety and tolerability of a transdermal oxycodone patch containing tocopheryl phosphate mixture (TPM)."( Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study.
Gavin, PD; Schlagheck, T; Shakib, S; Simon, LS; Smith, AJ, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
"The hydrophobicity of vitamin E poses transport and metabolic challenges to regulate its bioavailability and to prevent its accumulation in lipid-rich tissues such as adipose tissue, brain, and liver."( Water-Soluble Vitamin E-Tocopheryl Phosphate.
Zingg, JM,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutathione S-transferase omega-1Homo sapiens (human)IC50 (µMol)2.00000.02801.60404.6000AID1384567
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumGlutathione S-transferase omega-1Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionGlutathione S-transferase omega-1Homo sapiens (human)
positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ionGlutathione S-transferase omega-1Homo sapiens (human)
L-ascorbic acid metabolic processGlutathione S-transferase omega-1Homo sapiens (human)
xenobiotic catabolic processGlutathione S-transferase omega-1Homo sapiens (human)
negative regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase omega-1Homo sapiens (human)
positive regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase omega-1Homo sapiens (human)
cellular response to arsenic-containing substanceGlutathione S-transferase omega-1Homo sapiens (human)
cellular oxidant detoxificationGlutathione S-transferase omega-1Homo sapiens (human)
glutathione metabolic processGlutathione S-transferase omega-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
glutathione transferase activityGlutathione S-transferase omega-1Homo sapiens (human)
protein bindingGlutathione S-transferase omega-1Homo sapiens (human)
oxidoreductase activityGlutathione S-transferase omega-1Homo sapiens (human)
glutathione dehydrogenase (ascorbate) activityGlutathione S-transferase omega-1Homo sapiens (human)
methylarsonate reductase activityGlutathione S-transferase omega-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmGlutathione S-transferase omega-1Homo sapiens (human)
cytosolGlutathione S-transferase omega-1Homo sapiens (human)
extracellular exosomeGlutathione S-transferase omega-1Homo sapiens (human)
cytoplasmGlutathione S-transferase omega-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1384567Inhibition of human GSTO1-1 by MMA (V) reductase assay2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (70)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (34.29)18.7374
1990's3 (4.29)18.2507
2000's15 (21.43)29.6817
2010's27 (38.57)24.3611
2020's1 (1.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.68 (24.57)
Research Supply Index4.43 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (3.75%)5.53%
Reviews5 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other72 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]